Kopran Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹211 Cr +79.2% YoYSee revenue, profit and what management said. You are viewing Q4 FY26.
K

Kopran Ltd

Q4 FY26Pharmaceuticals & Biotechnology

Kopran Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹234Cr
+35.8% YoY
+20.5% QoQ
Net profit
₹19Cr
+94.9% YoY
+102% QoQ
Margin
14.08%
+4.2 pp YoY
+4.9 pp QoQ

Kopran Ltd Q4 FY26 key numbers

Revenue
Total Revenue FY 2025-26: Rs. 68,142 Lakhs (no prior year FY revenue for direct comparison on this page).

As stated in Kopran Ltd's Q4 FY26 investor presentation · published 24 Sept 2026. Reported figures, not investment advice.

Based on Kopran Ltd's Q4 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹271
Market cap₹1.3K Cr
P/E53.7

The short version

Q4 FY 2025-26 Revenue from Operations: Rs. 23,402 Lakhs. EBITDA for Q4 FY 2025-26: Rs. 4,057 Lakhs; up from Rs. 1,400 Lakhs in Q4 FY 2024-25 (almost 190% increase).

From Kopran Ltd's Q4 FY26 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Q4 FY 2025-26 Revenue from Operations: Rs. 23,402 Lakhs
  • Q4 FY 2024-25 Revenue from Operations: Rs. 17,236 Lakhs
  • Year-on-year revenue growth (Q4 FY 2025-26 vs Q4 FY 2024-25): Rs. 6,166 Lakhs increase (~35.8% growth)

2 more points from Kopran Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Kopran Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Focus on R&D to develop niche, high-value/high-volume APIs and intermediates (Page 15).
  • Capacity expansion planned as a strategic imperative (Page 15).
  • API and R&D facility located at Panoli (Gujarat) indicated as part of capacity expansion (Page 15).

2 more points from Kopran Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Kopran Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Kopran Ltd said on order book & pipeline — free account, 30 seconds.

Kopran Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Kopran Ltd Q4 FY26 results — key figures

Kopran Ltd Q4 FY26 reported results vs Q4 FY25, ₹ crore
₹ CrQ4 FY26Q4 FY25YoYQ3 FY26QoQ
Revenue234172+35.8%194+20.5%
Operating profit (EBITDA)3317+92.7%18+85.5%
Operating margin14.08%9.92%+4.2 pp9.14%+4.9 pp
Profit before tax2514+84.8%11+135.9%
Net profit (PAT)1910+94.9%9+102%
EPS (₹)3.912.01+94.5%1.94+101.5%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹211 Cr, net profit ₹4 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Balaxi Pharma (Q4 FY26)

    Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY

  • Accretion Pharmaceuticals (Q4 FY26)

    45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks

  • Gujarat Themis Biosyn (Q4 FY26)

    . Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.

  • Aptus Pharma (Q4 FY26)

    The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Kopran Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Kopran Ltd Q4 FY26 results?

Q4 FY 2025-26 Revenue from Operations: Rs. 23,402 Lakhs. EBITDA for Q4 FY 2025-26: Rs. 4,057 Lakhs; up from Rs. 1,400 Lakhs in Q4 FY 2024-25 (almost 190% increase).

What is Kopran Ltd share price analysis?

Kopran Ltd currently shows a neutral. The stock trades at a P/E of 53.7 with a market cap of ₹1,342 Cr. Investors should review the full earnings analysis for detailed insights.

Is Kopran Ltd planning capital expenditure?

Focus on R&D to develop niche, high-value/high-volume APIs and intermediates (Page 15). - Capacity expansion planned as a strategic imperative (Page 15). - API and R&D facility located at Panoli (Gujarat) indicated as part of capacity expansion (Page 15). - Manufacturing facilities with global accreditations at existing locations in Maharashtra: API vertical at MIDC Mahad (11,900 sq.

Keep Kopran Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.